This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
19, 2024) – Amber SpecialtyPharmacy announces the appointment of Jessica Ringena as its newest president. Ringena previously served as president of Vivid Clear Rx, a pharmacy benefit manager and subsidiary of Hy-Vee. The provider specializes in transplant, infusion and specialty care, including rare/orphan drugs and oncology.
For 340B-eligible hospitals dealing with increasingly tight bottom lines (which essentially means all 340B-eligible hospitals), an in-house specialtypharmacy offers enormous savings and revenue potential. What is a SpecialtyPharmacy? That’s roughly six times faster than overall growth in the specialty drug market.
As you will see below, mail and specialtypharmacies’ purchases of products that are eligible for 340B discounts have grown by an incredible 56% per year since 2017. That’s about six times faster than the overall mail and specialty market. Consequently, specialtypharmacies have gained a greater share of the 340B market.
The approval makes Relyvrio (sodium phenylbutyrate and taurursodiol) the first new therapy option for ALS – also known as motor neuron disease (MND) – since Mitsubishi Tanabe Pharma’s intravenous Radicava (edaravone) was cleared by the FDA in 2017. An oral version of edaravone was cleared this year.
Pharmacy benefit managers: transparency, accountability, and impact on patient care. Journal of Managed Care & SpecialtyPharmacy, 27(7), 903-907. Retrieved from https ://www.acc.org/latest-in- cardiology/articles/2017/02/21/12/42/barriers-to-new-medications-for-cardiovascular-disease-insights- from-cardiosurve?
Consequences of Obesity, last reviewed May 15, 2023, [link] www.cdc.gov/obesity/basics/consequences.html 6 Libbi Green and Patty Taddei-Allen, “Shifting Paradigms: Reframing Coverage of Antiobesity Medications for Plan Sponsors,” Journal of Managed Care & SpecialtyPharmacy 29, no. 14 National Health Council.
According to a 2017 report by the National Council on Disability, individuals with disabilities often face significant barriers in accessing health care services, including discriminatory attitudes from health care.9 The NHC supports the core tenet of the proposed § 84.56(b)(1), 9 Proposed paragraph 84.56(b)(1)(i) Has the promise been kept?
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content